BCL2 and acute myeloid leukemia: This activation induces autophagy in BC cell lines through ATP depletion [126], and it improve the antileukemic activity of BCL-2 inhibition through venetoclax, a selective inhibitor of the BCL-2 protein, that targets AML [127].